PPL 100

Drug Profile

PPL 100

Alternative Names: MK-8122; PL-100; PPL-100; TMB-607

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Ambrilia Biopharma
  • Developer Ambrilia Biopharma; TaiMed Biologics; Temple University
  • Class Aniline compounds; Antiretrovirals; Benzhydryl compounds; Carbamates; Phosphoric acid esters; Small molecules; Sulfonamides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 21 Nov 2016 Phase-I clinical trials in HIV infections (In volunteers) in USA (IM) (NCT03110549)
  • 21 Nov 2016 Phase-I clinical trials in HIV infections (In volunteers) in USA (SC) (NCT03110549)
  • 20 May 2016 PPl 100 (SC, IM) is still in preclinical development for HIV infections in Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top